Investor Presentation First Nine Months of 2023

90 Investor presentation First nine months of 2023 Novo Nordisk has a value market share of ~25% in the global human growth disorder market MS% Novo Nordisk leadership in competitive hGH market Value 25% 36% 37% 36% 33% 30% 19% 18% 14% 14% 14% 16% 17% 12% 13% 14% 15% 16% 38% 36% 36% 37% 37% 39% H1 2021 H2 2021 H1 2022 H2 2022 H1 2023 Q3 2023 Novo Nordisk Company A Company B Others SOGROYAⓇ somapacitan norditropin® (somatropin) injection A portfolio offering across markets SogroyaⓇ strategy • • Once-weekly efficacious treatment on par with NorditropinⓇ Simple and easy-to-use device Phase 3 trials toward broad range of indications (e.g. SGA, Turner, Noonan, ISS) to expand the market Approved for GHD in US, EU and Japan NorditropinⓇ strategy Apply a market-fit approach to support specific markets and patient groups Broad label across eight indications hGH: Human growth hormone; SGA: Small for gestational age, ISS; Idiopathic short stature Source: IQVIA, MAT Aug 2023. Due to contractual obligations competitor names are not disclosed. Company A and B represent actual companies; Market values are based on the list prices Novo NordiskⓇ

View entire presentation